Astrazeneca Ab

John McCauley

Marc Chapdelaine

Daniel Sohn

Carey Horchler

Timothy Davenport

Lucius Kemp

Edward Pierson

Markus Haeberlein

Glen E Ernst

Peter Robert Bernstein

William Frietze

Greg A Hostetler

Michael Balestra

David Nugiel

Lihong Shen

Bipinchandra Chaudhari

Dannielle Kissel

The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.

Ethanamine compounds and methods of using the same

Ethanamine compounds and methods of using the same 545

Compounds useful for the treatment of pain in accord with the following structural diagram, wherein R, Rand Rare any of a number of groups as defined in the specification and pharmaceutical compositions and methods of treatment utilising such compounds.

N-type calcium channel antagonists for the treatment of pain

Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HTand 5HTantagonists.

Therapeutic heterocyclic compounds

Provided herein is a compound having the formula (I):Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HTand 5HTantagonists.

Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HTantagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

Therapeutic chromone compounds

Compounds useful for the treatment of pain in accord with the following structural diagram,wherein R, R, R, Rand Rare any of a number of groups as defined in the specification, A and D are as defined in the specification, and pharmaceutical compositions and methods of treatment utilising such compounds.

Compounds having selective action at neuronal N-type calcium channels useful for the treatment of pain in accord with the following structural diagram,wherein R, Rand Rare a variety of groups as defined in the specification.

Growing community of inventors

Wilmington, DE, United States of America

John McCauley